Mirai Therapeutics

Updates : In-vitro Pre-clinical trials About Us: Mirai Therapeutics, an innovative early-stage company, is at the forefront of addressing the critical challenge in the field of nanomedicine - thromboinflammation. This detrimental immune response, characterized by inflammation and blood clot formation, leading to the rejection of the nanovehicles introduced into the bloodstream. Our main product is a novel venom-derived polypeptide that reduces thromboinflammation. This breakthrough allows nanovehicles to deliver their therapeutic payloads without triggering thromboinflammation. We also offer a service that measures thromboinflammation levels. This service provides valuable information for researchers, drug developers, enabling them to use nanovehicles safely and effectively in medical settings.